Oppenheimer restated their hold rating on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research report sent to investors on Tuesday, January 23rd. Oppenheimer also issued estimates for Teva Pharmaceutical Industries’ Q4 2017 earnings at $0.74 EPS, FY2017 earnings at $3.73 EPS and FY2018 earnings at $2.87 EPS.
Several other research analysts have also recently weighed in on TEVA. Mizuho reissued a hold rating and issued a $16.00 price objective on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 4th. BidaskClub raised Teva Pharmaceutical Industries from a strong sell rating to a sell rating in a research report on Thursday, September 28th. Cantor Fitzgerald set a $17.00 price target on Teva Pharmaceutical Industries and gave the company a hold rating in a research report on Monday, October 2nd. Wells Fargo & Co reaffirmed a market perform rating on shares of Teva Pharmaceutical Industries in a research report on Thursday, October 5th. Finally, Cowen reaffirmed a market perform rating and set a $18.00 price target (down previously from $30.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 4th. Ten investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and seven have assigned a buy rating to the company. Teva Pharmaceutical Industries has a consensus rating of Hold and an average price target of $21.26.
Teva Pharmaceutical Industries (NYSE:TEVA) traded up $0.81 during midday trading on Tuesday, hitting $19.33. The stock had a trading volume of 14,555,097 shares, compared to its average volume of 20,170,000. The company has a market capitalization of $19,890.00, a P/E ratio of -1.12, a price-to-earnings-growth ratio of 1.43 and a beta of 0.59. Teva Pharmaceutical Industries has a 52-week low of $10.85 and a 52-week high of $37.94. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.91 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.14. Teva Pharmaceutical Industries had a positive return on equity of 14.52% and a negative net margin of 72.66%. The business had revenue of $5.46 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter in the previous year, the firm earned $1.38 earnings per share. The business’s revenue was down 15.9% on a year-over-year basis. equities analysts expect that Teva Pharmaceutical Industries will post 2.69 EPS for the current year.
Several institutional investors have recently made changes to their positions in the company. Franklin Resources Inc. increased its position in shares of Teva Pharmaceutical Industries by 8.2% during the 4th quarter. Franklin Resources Inc. now owns 79,488,139 shares of the company’s stock valued at $1,506,309,000 after purchasing an additional 6,009,897 shares during the last quarter. Capital Research Global Investors boosted its holdings in Teva Pharmaceutical Industries by 13.8% during the 2nd quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after acquiring an additional 9,260,426 shares during the period. Northern Cross LLC boosted its holdings in Teva Pharmaceutical Industries by 14.0% during the 2nd quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock valued at $591,169,000 after acquiring an additional 2,184,172 shares during the period. Capital World Investors boosted its holdings in Teva Pharmaceutical Industries by 41.9% during the 2nd quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock valued at $367,686,000 after acquiring an additional 3,268,200 shares during the period. Finally, Two Sigma Advisers LP purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at about $118,487,000. Hedge funds and other institutional investors own 51.93% of the company’s stock.
WARNING: This report was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/14/oppenheimer-reaffirms-hold-rating-for-teva-pharmaceutical-industries-teva-2.html.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.